investors.23andme.com – MashupMD

Mashup Score: 2

23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation | 23andMe, Inc. - 2 day(s) ago

SUNNYVALE, Calif. and SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, and Mirador Therapeutics, a next-generation precision medicine company focused on developing first-in-class or best-in-class therapeutics for

Source: investors.23andme.com

Categories: General Medicine News, General HCPs

Tweet Tweets with this article
- matthewherper
  
  23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation https://t.co/FK0zyAvvpU

Mashup Score: 14

23andMe Appoints Three New Independent Directors to Board | 23andMe, Inc. - 24 day(s) ago

SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), a leading human genetics and preventive health company, today announced the appointments of Andre Fernandez, Jim Frankola, and Mark Jensen, three accomplished and experienced

Source: investors.23andme.com

Categories: General Medicine News, General HCPs

Tweet Tweets with this article
- matthewherper
  
  23andMe has named three new directors to its board. No real biotech or life science experience, and not really much in consumer products, either. A former Deloitte auditor, a WeWork CFO, and a Cloudera CFO. A lot of expertise, though, on restructuring. https://t.co/EuEuHl7v11